Gyre Therapeutics (GYRE) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $6.40, -1.08% vs the prior close of $6.47.
- Volume 108.80K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GYRE dips 1.1% to $6.40, a 1-month low, 4 down days in a row. Closed at $6.40, -1.08% vs the prior close of $6.47. Day range $6.40–$6.65, opened at $6.51.
GYRE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — GYRE dips 1.1% to $6.40, a 1-month low, 4 down days in a row
- Closed at $6.40, -1.08% vs the prior close of $6.47. Day range $6.40–$6.65, opened at $6.51.
- Volume was 108.80K shares, 0.9x its 50-day average of 124.52K.
- Price is -7.1% vs its 50-day average ($6.89) and -9.4% vs its 200-day average ($7.06).
- 52-week range $5.44–$9.42; today's close sits at 24% of that range, 32.1% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — GYRE slides 3.6% to $6.47, a 1-month low, 3 down days in a row
- Closed at $6.47, -3.58% vs the prior close of $6.71. Day range $6.44–$6.75, opened at $6.70.
- Volume was 162.80K shares, 1.3x its 50-day average of 122.52K.
- Price is -6.0% vs its 50-day average ($6.88) and -8.4% vs its 200-day average ($7.06).
- 52-week range $5.44–$9.42; today's close sits at 26% of that range, 31.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — GYRE dips 2.3% to $6.71
- Closed at $6.71, -2.33% vs the prior close of $6.87. Day range $6.71–$6.92, opened at $6.89.
- Volume was 85.10K shares, 0.7x its 50-day average of 121.90K.
- Price is -2.4% vs its 50-day average ($6.88) and -5.1% vs its 200-day average ($7.07).
- 52-week range $5.44–$9.42; today's close sits at 32% of that range, 28.8% below the 52-week high.
Oct 12, 2026 — GYRE dips 2.4% to $6.87
- Closed at $6.87, -2.41% vs the prior close of $7.04. Day range $6.85–$7.07, opened at $7.00.
- Volume was 82.00K shares, 0.7x its 50-day average of 121.22K.
- Price is +0.1% vs its 50-day average ($6.86) and -2.8% vs its 200-day average ($7.07).
- 52-week range $5.44–$9.42; today's close sits at 36% of that range, 27.1% below the 52-week high.
Oct 9, 2026 — GYRE jumps 4.1% to $7.04
- Closed at $7.04, +4.14% vs the prior close of $6.76. Day range $6.76–$7.09, opened at $6.80.
- Volume was 76.60K shares, 0.6x its 50-day average of 120.60K.
- Price is +2.9% vs its 50-day average ($6.84) and -0.5% vs its 200-day average ($7.07).
- 52-week range $5.44–$9.42; today's close sits at 40% of that range, 25.3% below the 52-week high.
Oct 8, 2026 — GYRE slides 4.0% to $6.76, 3 down days in a row
- Closed at $6.76, -3.98% vs the prior close of $7.04. Day range $6.74–$7.04, opened at $7.04.
- Volume was 82.80K shares, 0.7x its 50-day average of 120.27K.
- Price is -0.8% vs its 50-day average ($6.82) and -4.4% vs its 200-day average ($7.07).
- 52-week range $5.44–$9.42; today's close sits at 33% of that range, 28.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — GYRE dips 0.6% to $7.04
- Closed at $7.04, -0.56% vs the prior close of $7.08. Day range $6.99–$7.15, opened at $7.03.
- Volume was 99.20K shares, 0.8x its 50-day average of 118.92K.
- Price is +3.6% vs its 50-day average ($6.79) and -0.5% vs its 200-day average ($7.08).
- 52-week range $5.44–$9.42; today's close sits at 40% of that range, 25.3% below the 52-week high.
Oct 6, 2026 — GYRE slides 3.7% to $7.08
- Closed at $7.08, -3.67% vs the prior close of $7.35. Day range $7.01–$7.42, opened at $7.42.
- Volume was 134.00K shares, 1.1x its 50-day average of 117.11K.
- Price is +4.5% vs its 50-day average ($6.77) and +0.0% vs its 200-day average ($7.08).
- 52-week range $5.44–$9.42; today's close sits at 41% of that range, 24.8% below the 52-week high.
Oct 5, 2026 — GYRE jumps 3.4% to $7.35
- Closed at $7.35, +3.38% vs the prior close of $7.11. Day range $7.09–$7.43, opened at $7.17.
- Volume was 181.50K shares, 1.6x its 50-day average of 114.15K.
- Price is +8.8% vs its 50-day average ($6.75) and +3.8% vs its 200-day average ($7.08).
- 52-week range $5.44–$9.42; today's close sits at 48% of that range, 22.0% below the 52-week high.
Oct 2, 2026 — GYRE rises 1.6% to $7.11
- Closed at $7.11, +1.57% vs the prior close of $7.00. Day range $7.08–$7.35, opened at $7.09.
- Volume was 163.70K shares, 1.5x its 50-day average of 111.64K.
- Price is +5.7% vs its 50-day average ($6.73) and +0.4% vs its 200-day average ($7.08).
- 52-week range $5.44–$9.42; today's close sits at 42% of that range, 24.5% below the 52-week high.
GYRE latest news & SEC filings
Every SEC filing by or about GYRE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 31, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $29.11M (prior year $29.73M) (-2.1% vs Jun 30, 2025)
- Net income: -$14.27M (prior year -$2.24M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.12 (prior year -$0.03) (loss widened vs Jun 30, 2025)
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 4, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 15, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade GYRE
- Last results release: Aug 7, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 12, 2026, Nov 7, 2025. Based on that rhythm, the next report is likely around Nov 6, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.27% (largest 5.2%).
- Liquidity: about 207.54K shares (≈$1.33M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $6.40 vs a range of $5.44–$9.42 (24% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 18 sales; latest: Weiguo Ye sold 3,000 shares on Jun 18, 2026.
- Latest filings: 8-K Sep 1, 2026; 8-K Aug 26, 2026; 10-Q Aug 7, 2026.
- Share count: 111.51M shares outstanding (Aug 1, 2026), +15.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GYRE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 6.51 | 6.65 | 6.40 | 6.40 | 108.80K |
| Oct 14, 2026 | 6.70 | 6.75 | 6.44 | 6.47 | 162.80K |
| Oct 13, 2026 | 6.89 | 6.92 | 6.71 | 6.71 | 85.10K |
| Oct 12, 2026 | 7.00 | 7.07 | 6.85 | 6.87 | 82.00K |
| Oct 9, 2026 | 6.80 | 7.09 | 6.76 | 7.04 | 76.60K |
| Oct 8, 2026 | 7.04 | 7.04 | 6.74 | 6.76 | 82.80K |
| Oct 7, 2026 | 7.03 | 7.15 | 6.99 | 7.04 | 99.20K |
| Oct 6, 2026 | 7.42 | 7.42 | 7.01 | 7.08 | 134.00K |
| Oct 5, 2026 | 7.17 | 7.43 | 7.09 | 7.35 | 181.50K |
| Oct 2, 2026 | 7.09 | 7.35 | 7.08 | 7.11 | 163.70K |
| Oct 1, 2026 | 7.35 | 7.38 | 7.00 | 7.00 | 140.00K |
| Sep 30, 2026 | 7.32 | 7.38 | 7.13 | 7.33 | 159.80K |
| Sep 29, 2026 | 7.52 | 7.74 | 7.31 | 7.32 | 115.10K |
| Sep 28, 2026 | 7.35 | 7.56 | 7.30 | 7.49 | 137.00K |
| Sep 25, 2026 | 7.39 | 7.42 | 7.13 | 7.35 | 134.80K |
| Sep 24, 2026 | 7.40 | 7.44 | 6.81 | 7.33 | 327.70K |
| Sep 23, 2026 | 7.49 | 7.50 | 7.04 | 7.40 | 164.50K |
| Sep 22, 2026 | 7.40 | 7.61 | 7.26 | 7.49 | 227.00K |
| Sep 21, 2026 | 7.55 | 7.57 | 7.21 | 7.43 | 364.90K |
| Sep 18, 2026 | 7.12 | 7.56 | 7.10 | 7.55 | 1.20M |
About Gyre Therapeutics
Gyre Therapeutics (GYRE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1124105.
GYRE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gordon Carmichael | Director | Jun 30, 2026 |
| David M. Epstein | Director | Jun 30, 2026 |
| Maxwell Kirkby | Director | Aug 4, 2026 |
| Ying Luo | Chief Executive Officer | Jun 10, 2026 |
| Rodney L Nussbaum | Director | Jun 30, 2026 |
| Renate Parry | Director | Jun 30, 2026 |
| Dan Weng | Director | Jun 30, 2026 |
| Claire Weston | Director | Aug 4, 2026 |
| Ping Zhang | Director | Jun 30, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Joshua Benjamin Bergmann | GC and Corporate Secretary | Jun 10, 2026 |
| Ruoyu Chen | Chief Financial Officer | Jan 9, 2026 |
| Thomas Wilson Eastling | Chief Financial Officer | May 6, 2026 |
| Ying Luo | Chief Executive Officer | Jun 10, 2026 |
| Jialiang (Nmn) Wang | EVP, General Manager | May 7, 2026 |
| Yue Xiong | Chief Scientific Officer | May 7, 2026 |
| Weiguo Ye | Chief Operating Officer | Jun 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 18, 2026 | Weiguo Ye | Sale | 3,000 | $6.35 |
| Jun 11, 2026 | Weiguo Ye | Sale | 2,800 | $6.17 |
| Jun 10, 2026 | Weiguo Ye | Sale | 5,000 | $6.24 |
| Jun 10, 2026 | Weiguo Ye | Sale | 6,418 | $6.21 |
| Jun 9, 2026 | Weiguo Ye | Sale | 3,000 | $6.15 |
| Jun 9, 2026 | Weiguo Ye | Sale | 14,500 | $6.14 |
| Jun 5, 2026 | Weiguo Ye | Sale | 15,401 | $6.40 |
| Jun 4, 2026 | Weiguo Ye | Sale | 19,575 | $6.13 |
| May 26, 2026 | Weiguo Ye | Sale | 4,000 | $6.10 |
| May 22, 2026 | Weiguo Ye | Sale | 3,500 | $6.08 |
| May 21, 2026 | Weiguo Ye | Sale | 12,820 | $6.15 |
| May 20, 2026 | Weiguo Ye | Sale | 9,400 | $6.15 |
| May 19, 2026 | Weiguo Ye | Sale | 9,120 | $6.37 |
| May 18, 2026 | Weiguo Ye | Sale | 200 | $6.62 |
| May 15, 2026 | Weiguo Ye | Sale | 13,100 | $6.65 |
GYRE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $116.59M | $9.88M | 0.02 | $1.01M |
| Dec 31, 2024 | $105.76M | $17.90M | 0.05 | $-3.64M |
| Dec 31, 2023 | $113.45M | $-85.48M | -1.41 | $25.89M |
| Dec 31, 2022 | $102.29M | $4.31M | 0.03 | $10.68M |
| Dec 31, 2021 | $7.34M | $-87.93M | -2.87 | $-83.75M |
Latest balance sheet: total assets $199.25M, total liabilities $34.34M, cash $43.29M (as of Jun 30, 2026).
GYRE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 7, 2026 | 8-K Item 2.02 (results) | $6.67 |
| May 7, 2026 | 8-K Item 2.02 (results) | $7.07 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $7.81 |
| Nov 7, 2025 | 8-K Item 2.02 (results) | $7.21 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $7.07 |
| May 9, 2025 | 8-K Item 2.02 (results) | $9.53 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $12.28 |
| Feb 18, 2025 | 8-K Item 2.02 (results) | $12.70 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $14.48 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 26, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on GYRE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.